Minimal Residual Disease (MRD) Testing News and reporting on minimal residual disease testing. In Ongoing False Advertising Suit, Judge Allows Natera Counterclaims Against Guardant Health A federal judge denied four motions by Guardant but granted four others by the company. NeoGenomics Blood-Based Minimal Residual Disease Test Receives CE Mark NeoGenomics subsidiary Inivata has also submitted the RaDaR test to the MolDx program in the US for reimbursement. C2i Genomics, OncoDNA Enter Strategic Alliance for AI-Based Cancer Detection, Monitoring The companies and the Gustave Roussy Institute plan to initiate a clinical trial to test the utility of escalating treatments for cancers with high risk of recurrence. Personalis Reports Preliminary Q4 Revenues up More Than 2 Percent The company is expecting continued growth in its oncology orders in Q4 2021 to translate to significant revenue growth for that business next year. Genecast Minimal Residual Disease Test Plans Bolstered by New Lung Cancer Data Premium The company believes its fixed-panel, informatically guided approach can help capture the most possible patients with signs of residual or recurring cancer. Dec 1, 2021 Sequencing-Based MRD Detection in Bone Marrow May Predict ALL Relapse After CAR T-Cell Therapy Nov 30, 2021 Genetron Health Q3 Revenues up 36 Percent, Firm Announces AstraZeneca MRD Partnership Nov 19, 2021 Postsurgical ctDNA Analysis Predicts Adjuvant Chemotherapy Benefit in NSCLC Nov 18, 2021 Exact Sciences, Jefferson Health to Study Blood-Based Multicancer Early Detection Test Nov 17, 2021 Burning Rock Details Launch Plans for Three New Oncology Assays in 2022 Premium Nov 11, 2021 Palmetto Finalizes Medicare Coverage for MRD Cancer Testing Nov 4, 2021 NeoGenomics Preparing for Commercialization of Inivata MRD Test in 2022 Premium Nov 4, 2021 Personalis Q3 Revenues Climb 12 Percent Nov 3, 2021 Exact Sciences Gearing up for Busy 2022, Beyond Premium Oct 28, 2021 BGI Genomics Program Seeks to Validate Signatera Test for Colorectal Cancer Patients in China Premium Oct 22, 2021 Genetron Health, Fosun Ink Commercialization Deal for Seq-MRD Test in China Oct 19, 2021 Princess Margaret Cancer Centre, Inivata Partner on Clinical Liquid Biopsy Studies Oct 15, 2021 Natera Builds Data Backing Serial ctDNA Changes to Aid CRC Patient Management, Treatment Decisions Premium Sep 14, 2021 Exact Sciences, NSABP Validating Ability of ctDNA Test to Detect MRD in Colorectal Cancer Patients Sep 8, 2021 Natera Signatera Test to be Used in Study of MRD-Guided Treatment for Colon Cancer Patients Sep 1, 2021 Burning Rock Details Plans for Cancer Monitoring Assay, Adds New Data Supporting Early Detection Premium Aug 6, 2021 Guardant Health Laying Path for Future in Cancer Screening, Updates Launch Plans for CRC Assay Premium Aug 5, 2021 Guardant Health Q2 Revenues Grow 39 Percent Aug 4, 2021 Adaptive Biotechnologies Q2 Revenues Jump 83 Percent Jul 28, 2021 Strata Oncology Raises $90M in Series C Financing Load More Breaking News In Ongoing False Advertising Suit, Judge Allows Natera Counterclaims Against Guardant Health Centogene Strikes Rare Disease Target Discovery Deal With Insilico Medicine Dilated Cardiomyopathy Gene Mutations Point to Possible Therapeutic Strategy Ginkgo Bioworks Acquires Massachusetts COVID-19 Testing Firm Mainz Biomed Taps DCN Dx to Aid European Study of Enhanced ColoAlert Assay Parse Biosciences Partners With Research Instruments for Southeast Asia Distribution The Scan Transplant Tests Edited Pig Kidneys The Associated Press reports a University of Alabama-Birmingham team transplanted genetically modified pig kidneys into a brain-dead human patient. UK Changes Some Gene-Edited Crop Rules A new law may enable gene-edited crops to be sold in the UK within about five years, New Scientist says. Pill Works Against Omicron in Lab Pfizer's antiviral pill to treat SARS-CoV-2 appears to work against the Omicron variant, the Wall Street Journal reports. Nature Papers Find Genetic Risk Factor for Smell, Taste Loss in COVID-19; Analyze TB Granulomas In Nature this week: genome-wide association study find locus linked to the risk COVID-19 patients losing their sense of taste or smell, and more.